Shining a Light on IL-13: Optimizing Moderate-to-Severe Atopic Dermatitis Treatment in Daily Practice: An Online Activity

In this 45-minute activity from our Winter Clinical Hawaii Meeting, our expert faculty share clinical tips for treating patients with moderate-to-severe atopic dermatitis and insights for leveraging IL-13 targeted agents as part of a treatment pathway.

"The symptom negative impact on quality of life, I can tell you, as a practitioner, drives most of my decision making practically in the exam room. If a patient is truly miserable from their atopic dermatitis, I usually say, 'I don't care if your BSA is 5% or 90%, what influences me more is what is driving your quality of life.' If your quality of life is limited by your disease, to me, you're moderate-to-severe and I'm talking to you about systemic therapies."- Alexandra Golant, MD

This activity is supported by an educational grant from Lilly USA, LLC.